RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo

Chang,Liang; Gong,Fangchao; Cui,Youbin

doi:10.3892/mmr.2015.3477

RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo

Authors:
- Liang Chang
- Fangchao Gong
- Youbin Cui
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: March 12, 2015 https://doi.org/10.3892/mmr.2015.3477
Pages: 1197-1204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A disintegrin and metalloproteinase 9 (ADAM9) is a type I transmembrane protein that has been associated with cancer development and metastasis in various types of cancer. However, little is known about its role in non‑small cell lung cancer (NSCLC). The aim of the present study was to evaluate whether downregulation of ADAM9 affects cell proliferation, apoptosis, migration and invasion in NSCLC. Thus, a recombinant lentiviral small hairpin RNA expression vector carrying ADAM9 was constructed and infected into the human NSCLC cell line A549. Cell proliferation, apoptosis, migration and invasion in vitro and tumor growth in vivo were determined following downregulation of ADAM9 by RNA interference‑mediated ADAM9 gene silencing. It was found that downregulation of ADAM9 expression using an RNA silencing approach in A549 tumor cells significantly inhibited cell proliferation, migration and invasion, induced cell apoptosis in vitro, as well as suppressed in vivo tumor growth in an experimental mouse model of lung metastasis. These data indicate that ADAM9 is potentially an important new therapeutic target for the prevention of tumor growth in NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
4	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hayama M, Chida M, Karube Y, et al: One-step nucleic acid amplification for detection of lymph node metastasis in lung cancer. Ann Thorac Cardiovasc Surg. 20:181–184. 2014. View Article : Google Scholar
6	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243–6249. 2006. View Article : Google Scholar
7	Sun DS, Hu LK, Cai Y, et al: A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer. Asian Pac J Cancer Prev. 15:1233–1239. 2014. View Article : Google Scholar : PubMed/NCBI
8	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
9	Roy M, Luo YH, Ye M and Liu J: Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int. 2013:9647432013. View Article : Google Scholar : PubMed/NCBI
10	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
11	Becherer JD and Blobel CP: Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 54:101–123. 2003.PubMed/NCBI
12	Duffy MJ, McKiernan E, O’Donovan N and McGowan PM: Role of ADAMs in cancer formation and progression. Clin Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
13	Peduto L: ADAM9 as a potential target molecule in cancer. Curr Pharm Des. 15:2282–2287. 2009. View Article : Google Scholar : PubMed/NCBI
14	O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O’Higgins N and Duffy MJ: Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 105:754–761. 2003. View Article : Google Scholar
15	Tannapfel A, Anhalt K, Häusermann P, Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and Wittekind C: Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol. 201:238–249. 2003. View Article : Google Scholar : PubMed/NCBI
16	Carl-McGrath S, Lendeckel U, Ebert M, Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9, ADAM12 and ADAM15 are upregulated in gastric cancer. Int J Oncol. 26:17–24. 2005.
17	Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, et al: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 90:1053–1058. 2004. View Article : Google Scholar : PubMed/NCBI
18	Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grützmann R, et al: ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 54:1097–1106. 2008. View Article : Google Scholar
19	Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and Kristiansen G: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 8:1792008. View Article : Google Scholar : PubMed/NCBI
20	Zubel A, Flechtenmacher C, Edler L and Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Qi J, Chen N, Fu W, Zhou B and He A: High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer. Oncol Lett. 5:1461–1466. 2013.PubMed/NCBI
22	Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
23	Xu Q, Liu X, Cai Y, Yu Y and Chen W: RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells. Tumour Biol. 31:217–224. 2010. View Article : Google Scholar : PubMed/NCBI
24	Micocci KC, Martin AC, Montenegro Cde F, et al: ADAM9 silencing inhibits breast tumor cell invasion in vitro. Biochimie. 95:1371–1378. 2013. View Article : Google Scholar : PubMed/NCBI
25	Lin Y, Peng S and Yu H: RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012. View Article : Google Scholar
26	Klein T and Bischoff R: Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res. 10:17–33. 2011. View Article : Google Scholar
27	Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008. View Article : Google Scholar : PubMed/NCBI
28	Rocks N, Paulissen G, El Hour M, et al: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 90:369–379. 2008. View Article : Google Scholar
29	Peduto L, Reuter VE, Shaffer DR, Scher HI and Blobel CP: Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 65:9312–9319. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liu CM, Hsieh CL, He YC, et al: In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. PLoS One. 8:e537952013. View Article : Google Scholar : PubMed/NCBI
31	Hamada S, Satoh K, Fujibuchi W, et al: MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar
32	Zhang J and Hua ZC: Targeted gene silencing by small interfering RNA-based knock-down technology. Curr Pharm Biotechnol. 5:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
33	Uprichard SL: The therapeutic potential of RNA interference. FEBS Lett. 579:5996–6007. 2005. View Article : Google Scholar : PubMed/NCBI